AVEO (AVEO) Gets Disappointing Feedback from FDA on Tivozanib, to Evaluate Options to Confirm Activity
Tweet Send to a Friend
AVEO Oncology (Nasdaq: AVEO) announced that it has received written feedback from the U.S. Food and Drug Administration regarding a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
